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Background
Both antibodies and effector T cells appear to play
important roles in the protection against P. vivax and P.
falciparum infection. However, the partial protective
immunity induced by vaccination with recombinant C-
terminal region of merozoite surface protein (MSP-119)
is mediated largely by antibodies ([1,2]). Therefore, the
objective of the present study was to evaluate, when
PvMSP-119 and PfMSP-119 antigens were administered
as combination at a single site in mice by using different
immunization strategies (DNA/DNA, DNA/rprotein,
rprotein/rprotein). We found that mice immunized with
both recombinant antigens alone and in combination
using heterologous prime-boost strategies (prime with
DNA 100 ng and boost with recombinant protein 35
μg) lead to induced substantial levels of MSP-119 specif
c IgG1, IgG2a and IgG2b (a mixed Th1/Th2 type) anti-
bodies as measured by ELISA (Figure 1). In addition,
both antigens significantly increased IFNg responses in
mice immunized with both antigens in combination
using prime-boost strategy (Figure 2). rPfMSP-119 when
combined with rPvMSP-119 was not affects antibodies
or IFNg and IL-10 responses in prime-boost strategy.
Conclusion
The present results are encouraging to develop a multi-
species human malaria vaccine against asexual blood
stage of P. vivax and P. falciparum. Further study is
needed to evaluate the protective efficacy of this vaccine
in non-human primates.
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Figure 1 (abstract P64). Antibody responses to rPvMSP-119(a) and rPfMSP-119(b) in immunized mice.
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Figure 2 (abstract P64). IFNg responses to rPvMSP-119(a) and rPfMSP-119(b) in immunized mice.
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